Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 1/20 | 1.00 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31348922 | 1.00 | RPS6KB1 (1.00) | RPS6KB1GRM2LMNADRD4PIK3CD | |
| SCHEMBL30041857 | 0.93 | RPS6KB1 (0.86) | RPS6KB1GRM2LMNADRD4 | |
| SCHEMBL17714406 | 0.93 | RPS6KB1 (0.86) | RPS6KB1GRM2LMNADRD4 | |
| SCHEMBL30040497 | 0.86 | RPS6KB1 (0.75) | RPS6KB1GRM2LMNADRD4 | |
| SCHEMBL23932538 | 0.86 | RPS6KB1 (0.75) | RPS6KB1GRM2LMNADRD4 | |
| SCHEMBL23964274 | 0.82 | RPS6KB1 (0.69) | RPS6KB1GRM2LMNADRD4PIK3CD | |
| SCHEMBL30042095 | 0.82 | RPS6KB1 (0.69) | RPS6KB1GRM2LMNADRD4PIK3CD | |
| SCHEMBL23932512 | 0.81 | RPS6KB1 (0.68) | RPS6KB1GRM2LMNADRD4 | |
| SCHEMBL23932547 | 0.80 | RPS6KB1 (0.66) | RPS6KB1DRD4PIK3CDPIK3CBSLC2A1 | |
| SCHEMBL25186830 | 0.79 | RPS6KB1 (0.65) | RPS6KB1LMNADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3947736-B1 | PROGNOSIS METHOD OF CANCER | CENTRE NAT RECH SCIENT (FR) | 2026-03-11 | — | — | EP | claimed |
| WO-2025235403-A1 | DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-11-13 | — | — | WO | claimed |
| US-20250057840-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES WITH ISOCITRATE DEHYDROGENASE 1/2 MUTATIONS | FRED HUTCHINSON CANCER CENTER (US) | 2025-02-20 | — | — | US | claimed |
| CN-119112898-A | Medicine for treating Alzheimer disease learning and memory disorder and application thereof | 徐州医科大学 | 2024-12-13 | — | — | CN | claimed |
| CN-113786409-B | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | 甫康（上海）健康科技有限责任公司 | 2024-04-02 | — | — | CN | claimed |
| US-11801232-B2 | Targeting of ARID1A-deficient cancers by inhibiting de novo pyrimidine synthesis pathway | YALE UNIVERSITY (US) | 2023-10-31 | — | — | US | claimed |
| US-20230220395-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION | UNIVERSITY OF MASSACHUSETTS | 2023-07-13 | — | — | US | claimed |
| CN-116322773-A | Methods and compositions for treating age-related macular degeneration | 马萨诸塞大学 | 2023-06-23 | — | — | CN | claimed |
| US-20230190736-A1 | SMALL MOLECULE THERAPEUTICS FOR THE TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-06-22 | — | — | US | claimed |
| EP-4138779-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION | University of Massachusetts (US) | 2023-03-01 | — | — | EP | claimed |
| EP-3337477-B1 | COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT | CONVALIFE SHANGHAI CO LTD (CN) | 2023-02-01 | — | — | EP | claimed |
| US-20220204561-A1 | PEPTIDE-BASED NON-PROTEINACEOUS CARGO DELIVERY | FELDAN BIO INC. (CA) | 2022-06-30 | — | — | US | claimed |
| US-20220186321-A1 | PROGNOSIS METHOD OF CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-06-16 | — | — | US | claimed |
| EP-3947736-A1 | PROGNOSIS METHOD OF CANCER | Centre national de la recherche scientifique (FR) | 2022-02-09 | — | — | EP | claimed |
| US-12636370-B2 | Combination therapy for treatment of cancer | INSTITUTE FOR CANCER RESEARCH (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260124274-A1 | METHODS OF INCREASING READTHROUGH OF A PREMATURE TERMINATION CODON | UNIV RAMOT (IL) | 2026-05-07 | — | — | US | disclosed |
| US-20260115287-A1 | T CELL THERAPY IN PATIENTS WHO HAVE HAD PRIOR STEM CELL TRANSPLANT | CELGENE CORPORATION (US) | 2026-04-30 | — | — | US | disclosed |
| US-20220031673-A1 | Novel Compositions and Methods for Treating or Preventing Dermal Disorders | UNIV DREXEL (US) | 2022-02-03 | — | — | US | disclosed |
| WO-2021216665-A9 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021216665-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124274-A1 | METHODS OF INCREASING READTHROUGH OF A PREMATURE TERMINATION CODON | RNMT, TRMT1L, UPF1 | RPS6KB1 490/4885GRM2 4338/4885LMNA 1193/4885 |
| US-12636370-B2 | Combination therapy for treatment of cancer | RB1, MDM2, PHKB | RPS6KB1 160/4885GRM2 2828/4885LMNA 1297/4885 |
| US-20220031673-A1 | Novel Compositions and Methods for Treating or Preventing Dermal Disorders | MTOR, RPTOR, DEPTOR | RPS6KB1 84/4885GRM2 4856/4885LMNA 293/4885 |
| US-20260115287-A1 | T CELL THERAPY IN PATIENTS WHO HAVE HAD PRIOR STEM CELL TRANSPLANT | PBK, ICOS, CD47 | RPS6KB1 3136/4885GRM2 4306/4885LMNA 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.